Tumor immune microenvironment components and the other markers can predict the efficacy of neoadjuvant chemotherapy for breast cancer

Zhang, Weiqian; Xu, Ke; Li, Zhengfa; Wang, Linwei; Chen, Honglei

doi:10.1007/s12094-023-03075-y

Cited by 6 publications

(6 citation statements)

References 107 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In conclusion, understanding the complex interactions between immune cells, immune CIs, and cytokines provides valuable insights into the therapeutic implications of targeting the immune microenvironment [14,260]. By embracing personalized treatment approaches based on individual immune profiles, we can unlock the full potential of immunotherapies and enhance the prospects of successful outcomes for BC patients.…”

Section: Discussionmentioning

confidence: 99%

“…Future research should focus on patient-specific approaches based on individual immune profiles, genomic alterations, and tumor characteristics [259]. Combination therapies targeting cancer cells and the immune system offer promising therapeutic interventions [260]. Further research is needed to identify reliable biomarkers, understand resistance mechanisms, optimize treatment sequencing, explore long-term immune memory, and develop personalized immunotherapeutic strategies.…”

Section: Biomarkers and Future Directionsmentioning

confidence: 99%

See 1 more Smart Citation

Unveiling the Immune Microenvironment’s Role in Breast Cancer: A Glimpse into Promising Frontiers

Kotsifaki,

Alevizopoulos,

Dimopoulou

et al. 2023

IJMS

View full text Add to dashboard Cite

Breast cancer (BC), one of the most widespread and devastating diseases affecting women worldwide, presents a significant public health challenge. This review explores the emerging frontiers of research focused on deciphering the intricate interplay between BC cells and the immune microenvironment. Understanding the role of the immune system in BC is critical as it holds promise for novel therapeutic approaches and precision medicine strategies. This review delves into the current literature regarding the immune microenvironment’s contribution to BC initiation, progression, and metastasis. It examines the complex mechanisms by which BC cells interact with various immune cell populations, including tumor-infiltrating lymphocytes (TILs) and tumor-associated macrophages (TAMs). Furthermore, this review highlights the impact of immune-related factors, such as cytokines and immune checkpoint molecules. Additionally, this comprehensive analysis sheds light on the potential biomarkers associated with the immune response in BC, enabling early diagnosis and prognostic assessment. The therapeutic implications of targeting the immune microenvironment are also explored, encompassing immunotherapeutic strategies and combination therapies to enhance treatment efficacy. The significance of this review lies in its potential to pave the way for novel therapeutic interventions, providing clinicians and researchers with essential knowledge to design targeted and personalized treatment regimens for BC patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Biomarkers and Future Directionsmentioning

confidence: 99%

Unveiling the Immune Microenvironment’s Role in Breast Cancer: A Glimpse into Promising Frontiers

Kotsifaki,

Alevizopoulos,

Dimopoulou

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…Research has shown that cells in the TME can be regarded as biomarkers of treatment response. These cells can indirectly reflect the immune status of tumor cells and their hosts, affect tumor development and indicate the pCR after NACT ( 15 ). Many comprehensive treatments for BC involve interactions with the TME of the host.…”

Section: The Cell Compositions Of the Tumor Microenvironmentmentioning

confidence: 99%

The cellular composition of the tumor microenvironment is an important marker for predicting therapeutic efficacy in breast cancer

Dou,

Li,

Zhang

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

At present, the incidence rate of breast cancer ranks first among new-onset malignant tumors in women. The tumor microenvironment is a hot topic in tumor research. There are abundant cells in the tumor microenvironment that play a protumor or antitumor role in breast cancer. During the treatment of breast cancer, different cells have different influences on the therapeutic response. And after treatment, the cellular composition in the tumor microenvironment will change too. In this review, we summarize the interactions between different cell compositions (such as immune cells, fibroblasts, endothelial cells, and adipocytes) in the tumor microenvironment and the treatment mechanism of breast cancer. We believe that detecting the cellular composition of the tumor microenvironment is able to predict the therapeutic efficacy of treatments for breast cancer and benefit to combination administration of breast cancer.

show abstract

“…In contrast, increased TILs characterized by high CD3 + T cells and CD68 + macrophages post-chemotherapy is associated with worse prognosis ( 132 ). These findings suggest differential prognostic value of immunologic infiltrates across cancers, calling for specific biomarkers for each cancer type or subtype and treatment ( 133 ).…”

Section: Biomarkers Indicating Immune Responsiveness To Chemotherapy ...mentioning

confidence: 99%

Immunogenic chemotherapy: great potential for improving response rates

Huang,

Ren,

Yang

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

The activation of anti-tumor immunity is critical in treating cancers. Recent studies indicate that several chemotherapy agents can stimulate anti-tumor immunity by inducing immunogenic cell death and durably eradicate tumors. This suggests that immunogenic chemotherapy holds great potential for improving response rates. However, chemotherapy in practice has only had limited success in inducing long-term survival or cure of cancers when used either alone or in combination with immunotherapy. We think that this is because the importance of dose, schedule, and tumor model dependence of chemotherapy-activated anti-tumor immunity is under-appreciated. Here, we review immune modulation function of representative chemotherapy agents and propose a model of immunogenic chemotherapy-induced long-lasting responses that rely on synergetic interaction between killing tumor cells and inducing anti-tumor immunity. We comb through several chemotherapy treatment schedules, and identify the needs for chemotherapy dose and schedule optimization and combination therapy with immunotherapy when chemotherapy dosage or immune responsiveness is too low. We further review tumor cell intrinsic factors that affect the optimal chemotherapy dose and schedule. Lastly, we review the biomarkers indicating responsiveness to chemotherapy and/or immunotherapy treatments. A deep understanding of how chemotherapy activates anti-tumor immunity and how to monitor its responsiveness can lead to the development of more effective chemotherapy or chemo-immunotherapy, thereby improving the efficacy of cancer treatment.

show abstract

Tumor immune microenvironment components and the other markers can predict the efficacy of neoadjuvant chemotherapy for breast cancer

Cited by 6 publications

References 107 publications

Unveiling the Immune Microenvironment’s Role in Breast Cancer: A Glimpse into Promising Frontiers

Unveiling the Immune Microenvironment’s Role in Breast Cancer: A Glimpse into Promising Frontiers

The cellular composition of the tumor microenvironment is an important marker for predicting therapeutic efficacy in breast cancer

Immunogenic chemotherapy: great potential for improving response rates

Contact Info

Product

Resources

About